How should methotrexate be initiated, titrated, monitored, and what are its contraindications for inflammatory conditions such as rheumatoid arthritis or psoriasis?

Methotrexate for Inflammatory Conditions: Initiation, Titration, Monitoring, and Contraindications

Starting Dose and Initial Administration

Start methotrexate at 10-15 mg once weekly by mouth, clearly designating the specific day of the week to prevent life-threatening daily dosing errors. 1, 2

• The American Academy of Dermatology emphasizes that oral methotrexate must be taken once weekly at doses typically ranging from 7.5 to 25 mg, with the day of the week clearly marked on prescriptions 1
• For patients over 70 years or those with renal impairment, start at lower doses (2.5-5 mg weekly) to minimize toxicity risk 2
• A test dose of 2.5-5 mg is recommended before starting full therapy, especially in patients with impaired kidney function 2
• The initial dose should not exceed 0.2 mg/kg body weight 2
• Prescriptions should never be written on a PRN basis, as mistaken daily use has led to fatal toxicity 3

Dose Escalation Strategy

Increase methotrexate by 2.5-5 mg every 2-4 weeks based on clinical response and tolerability, up to a maximum of 20-30 mg weekly. 1, 2

• Allow at least 4 weeks after each dose adjustment to assess clinical response before making further changes 2
• Rapid dose escalation is appropriate if inadequate response occurs, with increments of 2.5-5 mg every 2-4 weeks up to 15-20 mg or even 25 mg weekly within approximately 8 weeks 1, 4
• If no adequate response is achieved after 12-16 weeks at maximum tolerated dose, consider alternative therapy 2

Route of Administration

Begin with oral administration, but switch to subcutaneous methotrexate if gastrointestinal side effects, inadequate response, or compliance issues occur before abandoning the drug entirely. 1

• Oral administration is preferred initially for convenience and patient preference 1
• Subcutaneous methotrexate has superior bioavailability and may reduce mucosal toxicity including oral ulcers 1
• Consider parenteral route for: compliance issues, non-effectiveness of oral treatment, gastrointestinal side effects, polypharmacy, obesity (especially if doses >20 mg/week are required), very active disease, or to avoid administration errors 4

Mandatory Folic Acid Supplementation

Prescribe at least 5 mg of folic acid per week with methotrexate, taken on a different day than the methotrexate dose. 1, 2

• Folic acid supplementation is mandatory to reduce gastrointestinal, hepatic, and mucosal adverse effects 1
• Do not take folic acid on the same day as methotrexate to avoid competitive cellular uptake 1
• Some guidelines suggest 1-5 mg daily (except on methotrexate day) to reduce incidence of side effects 2

Baseline Monitoring Requirements

Before starting methotrexate, obtain: complete blood count with differential and platelets, AST, ALT, albumin, creatinine with calculated clearance, hepatitis B and C serology, and chest X-ray. 1, 3, 5

• These baseline tests are mandatory per FDA labeling and multiple guidelines 3, 5
• In patients with respiratory history or current symptoms, add pulmonary function tests with diffusing capacity for carbon monoxide 5

Ongoing Monitoring Schedule

Monitor complete blood count and liver function tests every 1-1.5 months initially, then every 1-3 months once stable. 1, 4

• During initial therapy or dose changes, or during periods of increased risk (e.g., dehydration), more frequent monitoring is indicated 3
• Renal function should be checked every 1-2 months 3
• More frequent monitoring (at least monthly) is recommended for the first 3 months, then every 4-12 weeks 5
• Transient liver function test abnormalities are common and usually not cause for modification of therapy 3
• Persistent liver function test abnormalities and/or depression of serum albumin may indicate serious liver toxicity requiring evaluation 3

Management of Intolerance

If oral ulcers or gastrointestinal symptoms develop: first try split dosing over 24 hours, then increase folic acid supplementation, and finally switch to subcutaneous administration. 1

• Methotrexate can be split into 3 doses given every 12 hours over 24 hours if gastrointestinal side effects are problematic 1
• This stepwise approach allows optimization before abandoning an effective therapy 1

Absolute Contraindications

Methotrexate is absolutely contraindicated in pregnancy, breastfeeding, patients with alcoholic liver disease or chronic liver disease, immunodeficiency syndromes, and preexisting blood dyscrasias. 3

• Women of childbearing age must use contraception and wait at least 3 months (at least one ovulatory cycle) after discontinuation before attempting pregnancy 1, 3
• Male patients should avoid fathering children during and for a minimum of 3 months after therapy 3
• Contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes 3
• Contraindicated in patients with preexisting bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia 3
• Contraindicated in patients with known hypersensitivity to methotrexate 3

Critical Safety Warnings

Avoid alcohol consumption (>1 drink/day for women, >2 drinks/day for men) and use extreme caution with concomitant NSAIDs, especially at higher methotrexate doses. 1, 3

• NSAIDs should not be administered prior to or concomitantly with high-dose methotrexate 3
• Concomitant administration of some NSAIDs with high-dose methotrexate has resulted in deaths from severe hematologic and gastrointestinal toxicity 3
• Caution is warranted even with lower doses used in rheumatoid arthritis (7.5-15 mg/week), though studies have usually included concurrent NSAID use without apparent problems 3
• Renal impairment increases methotrexate toxicity risk; consider dose reduction or test dose in patients with impaired kidney function 1
• Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions, requiring careful monitoring and potential dose reduction or discontinuation 3

Life-Threatening Toxicities to Monitor

Immediately discontinue methotrexate if pulmonary symptoms (especially dry, nonproductive cough), severe diarrhea, or ulcerative stomatitis develop. 3

• Methotrexate-induced lung disease (acute or chronic interstitial pneumonitis) may occur at any time during therapy, even at low doses, and is not always fully reversible 3
• Pulmonary symptoms require interruption of treatment and immediate investigation 3
• Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur 3
• Unexpectedly severe (sometimes fatal) bone marrow suppression and aplastic anemia have been reported 3

Common Prescribing Pitfalls

The most critical error is patients mistakenly taking methotrexate daily instead of weekly, which has led to fatal toxicity. 1, 3

• Both physician and pharmacist must emphasize to patients that the dose is taken weekly, not daily 3
• Clearly designate the specific day of the week on all prescriptions 1
• Never write prescriptions on a PRN basis 3
• Ensure patients understand early signs and symptoms of toxicity and the need for prompt physician contact 3